TELA Bio Announces U.S. Commercial Launch of OviTex PRS Long

TELA Bio Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

16.08.2023 - New addition expands reconstruction options for surgeons and patientsMALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue ... Seite 1

Related Keywords

Antony Koblish , Howard Langstein , Bio Inc , Nasdaq , Term Resorbable , Plastic Surgery University , Rochester Medical , Tela Bio Chart , Ela Bio Kurs , Ela Bio Aktie ,

© 2025 Vimarsana